Want to see MPLT full AI Analyst Report?
MPLT Stock Chart & Stats
$17.49
--
Market closed
$17.49
--
Day’s Range― - ―
52-Week Range$9.10 - $40.43
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.63K
Market Cap
$554.89M
Enterprise Value-$27.06M
Total Cash (Recent Filing)$310.11M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)―
Beta1.02
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,618,164
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit47.14
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$33.20Price Target Upside89.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a sizable equity base provide durable financial flexibility for an R&D-intensive biotech. This capitalization can fund continued trials and support strategic options (partnerships, acquisitions, or catch-up trials) over the next 2–6 months without immediate solvency risk.
Positive Schizophrenia Phase 2A positive, statistically significant Phase 2 with favorable tolerability and cognitive signals establishes a clear development path toward a pivotal program. This finding materially improves the program's probability of success and can guide regulatory strategy, partnerships, and resource allocation over the medium term.
Pipeline Expansion & Fast TrackBroader therapeutic coverage (schizophrenia, autism, Alzheimer’s psychosis) reduces binary dependence on a single program and spreads clinical risk. Fast Track for Alzheimer’s psychosis enhances regulatory engagement and potential acceleration, improving chances of earlier approvals or expedited development timelines.
Bears Say
Pre-Revenue With Rising LossesA pre-revenue model with sharply widening losses increases reliance on external capital and heightens dilution risk. Sustained negative earnings mean management must prioritize financing or milestone monetization, which can constrain strategic optionality and pressure operations over coming quarters.
High Cash BurnSubstantial and accelerating cash burn consumes balance sheet resources quickly, shortening runway absent new funding. Consistent negative operating and free cash flow forces financing decisions that can dilute shareholders or divert management attention from clinical execution.
Management / Governance DisruptionA senior finance departure for non-operational reasons introduces governance and execution risk during critical development milestones. Leadership turnover can slow budgeting, reporting, and fundraising, potentially complicating partnerships or capital raises while pivotal trials proceed.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $9.10 and its highest was $40.43 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $554.89M.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 42,618,164 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.20 (89.82% Upside)
$33.20 (89.82% Upside)
Blogger Sentiment
Neutral
MPLT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 301.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 44%
Bearish news 56%
Bearish news 56%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
275.37%
Trailing 12-Months
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$33.20
▲(89.82% Upside)
Ownership Overview
65.30% Insiders
7.59% Mutual Funds
2.20% Other Institutional Investors
19.97% Public Companies and
Individual Investors